SCHEMBL4244256

SCHEMBL4244256

CCOCCNC(=O)c1cc2c(nc(C)n2C)c2c1CCC1(Cc3ccccc3C1)N2

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
HPGD P15428 4/20 0.39
KDM4E B2RXH2 4/20 0.39
NAMPT P43490 2/20 0.35
TP53 P04637 2/20 0.33
HTT P42858 1/20 0.32
MAPT P10636 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CACNA1G O43497 1/20 0.32
CACNA1H O95180 1/20 0.32
CACNA1I Q9P0X4 1/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
GAA P10253 1/20 0.32
HSD17B10 Q99714 1/20 0.32
PDE7B Q9NP56 1/20 0.32
HCN1 O60741 1/20 0.31
HCN4 Q9Y3Q4 1/20 0.31
BLM P54132 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4242410 0.93 ALDH1A1 (0.36) ALDH1A1HPGDKDM4EHTTMAPT
Hydrochloric Acid SCHEMBL4245930 0.92 ALDH1A1 (0.35) ALDH1A1HPGDKDM4EHTTMAPT
Malonic Acid SCHEMBL4246390 0.90 ALDH1A1 (0.34) ALDH1A1HPGDKDM4EHTTMAPT
SCHEMBL4239937 0.89 CDK2 (0.34) ALDH1A1HPGDKDM4EMAPTLMNA
SCHEMBL4235958 0.89 CHIA (0.32) KDM4EHSD17B10HCN1HCN4
Fumaric Acid SCHEMBL4244556 0.88 KMT2A (0.33) ALDH1A1HPGDKDM4EHTTMAPT
Maleic Acid SCHEMBL4244553 0.88 KMT2A (0.33) ALDH1A1HPGDKDM4EHTTMAPT
SCHEMBL4241781 0.88 OPRL1 (0.34) ALDH1A1HPGDKDM4EHTTMAPT
SCHEMBL4241846 0.86 HCN1 (0.30) HCN1HCN4
SCHEMBL4239785 0.85 ALDH1A1 (0.35) ALDH1A1HPGDKDM4ETP53HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090093473-A1 Spiro-benzimidazoles as inhibitors of gastric acid secretion NYCOMED GMBH (DE) 2009-04-09 US claimed
EP-1899338-A1 SPIRO-BENZIMIDAZOLES AS INHIBITORS OF GASTRIC ACID SECRETION Nycomed GmbH (DE) 2008-03-19 EP claimed
WO-2006134111-A1 SPIRO-BENZIMIDAZOLES AS INHIBITORS OF GASTRIC ACID SECRETION NYCOMED GMBH (DE) 2006-12-21 WO claimed
US-20090093473-A1 Spiro-benzimidazoles as inhibitors of gastric acid secretion NYCOMED GMBH (DE) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093473-A1 Spiro-benzimidazoles as inhibitors of gastric acid secretion GIPR, PGC, SLC10A2 ALDH1A1 187/4885HPGD 304/4885KDM4E 4320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.